

Special Issue

Diagnostics and Vaccine Development for Emerging Infectious Diseases

Message from the Guest Editor

This Special Issue focuses on the design of diagnostics and vaccines for different types of emerging infectious diseases. Examples include HIV infection, filovirus diseases, flavivirus diseases, Nipah virus infection, and the coronaviruses. We need to continually develop better diagnostic tools that can provide early detection of pathogens, agents of infectious diseases. Second, given the diversity of these pathogens and the heterogeneity of ways in which the human immune system may be primed to control and provide protection, there is an urgent need to design and develop multiple different platforms for next-generation vaccines. It is very important that we identify precise and practical targets for designing effective diagnostics that can be quickly translated into development. In addition, increasing the availability of new vaccine design platforms such as mRNA and viral vector technologies as well as the progress in peptide-based multi-epitope vaccines, including in identifying precise and potent targets for the design of effective vaccines against emerging infectious diseases, is needed now more than ever. I look forward to receiving your contributions.

Guest Editor

Dr. Syed Faraz Ahmed

Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC 3010, Australia

Deadline for manuscript submissions

closed (10 May 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/132939

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).